01.

Sungja Cho, MD, Ph.D. - CEO, Neudive

neudive

2025. 01. Hononred the CES Innovation Awards in

History of Neudive

which can be played anytime, anywhere.

and extensive experience.

Digital Health Category

2025. 01. Designated as an innovative medical device (general)


by the Ministry of Food and Drug Safety

2022.01. Established Neudive Inc.

neudive.

buddy-in is a digital therapeutic designed to enhance social skills

buddy | State | State



is a digital therapeutic designed for children and adolescents with autism spectrum disorder (ASD) and social communication disorder (SCD)

Its main project, the app-based social skills training program "Buddy-in,"

through digital social skills training.

Buddy-in is Neudive's flagship digital therapeutic product,

created as an engaging, game-like application. It specifically targets
individuals with ASD and social communication challenges, helping them

improve their social skills through structured and interactive exercises.

O2.

Hyosang Lee, Ph.D. - Chair, Department of Brain Sciences, DGIST

DGIST

Institute of Science & Technology



The Department of Brain Sciences at DGIST is a leading interdisciplinary research and education center focused on understanding brain function and developing treatments for neurological disorders. The department comprises 31 faculty members, including experts in neuroscience, cognitive science, and relative fields.

Research spans neural development, aging, brain diseases, and brain-inspired technologies, with notable studies on chronic stress, neurodegeneration,

convergence-based curriculum, the department fosters collaboration across

biology, engineering, and computation to advance brain science and train

and cognitive decline. Equipped with cutting-edge facilities and a

next-generation researchers.


Site Visits

O1.
Institute of Membrane Proteins

시 포막다백집여구소

Institute of Membrane Proteins

州至野野町置包字本



Threebrook Therapeutics



at enhancing cognitive function and protecting brain nerve cells.

Three Brooks Therapeutics is also engaged in the development of novel drugs targeting fundamental degenerative brain diseases. This is achieved through the development of ion channel activators that regulate lysosomal and autophagy functions. In addition, the company offers electrophysiological evaluation services based on its proprietary organelle electrophysiology technology.